242 related articles for article (PubMed ID: 35967294)
1. Distinct immune stimulatory effects of anti-human VISTA antibodies are determined by Fc-receptor interaction.
Mostböck S; Wu HH; Fenn T; Riegler B; Strahlhofer S; Huang Y; Hansen G; Kroe-Barrett R; Tirapu I; Vogt AB
Front Immunol; 2022; 13():862757. PubMed ID: 35967294
[TBL] [Abstract][Full Text] [Related]
2. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.
Thakkar D; Paliwal S; Dharmadhikari B; Guan S; Liu L; Kar S; Tulsian NK; Gruber JJ; DiMascio L; Paszkiewicz KH; Ingram PJ; D Boyd-Kirkup J
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35131861
[TBL] [Abstract][Full Text] [Related]
3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
5. A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors.
Iadonato S; Ovechkina Y; Lustig K; Cross J; Eyde N; Frazier E; Kabi N; Katz C; Lance R; Peckham D; Sridhar S; Talbaux C; Tihista I; Xu M; Guillaudeux T
Front Immunol; 2023; 14():1311658. PubMed ID: 38152397
[TBL] [Abstract][Full Text] [Related]
6. Fc receptors for mouse IgG1 on human monocytes: polymorphism and role in antibody-induced T cell proliferation.
Tax WJ; Hermes FF; Willems RW; Capel PJ; Koene RA
J Immunol; 1984 Sep; 133(3):1185-9. PubMed ID: 6235283
[TBL] [Abstract][Full Text] [Related]
7. Distinct effector functions mediated by Fc regions of bovine IgG subclasses and their interaction with Fc gamma receptors.
Noble A; Paudyal B; Schwartz JC; Mwangi W; Munir D; Tchilian E; Hammond JA; Graham SP
Front Immunol; 2023; 14():1286903. PubMed ID: 38077405
[TBL] [Abstract][Full Text] [Related]
8. VISTA deficiency attenuates antibody-induced arthritis and alters macrophage gene expression in response to simulated immune complexes.
Ceeraz S; Eszterhas SK; Sergent PA; Armstrong DA; Ashare A; Broughton T; Wang L; Pechenick D; Burns CM; Noelle RJ; Vincenti MP; Fava RA
Arthritis Res Ther; 2017 Dec; 19(1):270. PubMed ID: 29216931
[TBL] [Abstract][Full Text] [Related]
9. Murine monoclonal IgG antibodies: differences in their IgG isotypes can affect the antibody effector activity when using human cells.
Lobo PI; Patel HC
Immunol Cell Biol; 1997 Jun; 75(3):267-74. PubMed ID: 9243292
[TBL] [Abstract][Full Text] [Related]
10. The functional activity of Fc gamma RII and Fc gamma RIII on subsets of human lymphocytes.
Hadley AG; Zupanska B; Kumpel BM; Leader KA
Immunology; 1992 Jul; 76(3):446-51. PubMed ID: 1356095
[TBL] [Abstract][Full Text] [Related]
11. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
12. Fc gamma RI and Fc gamma RII on monocytes and granulocytes are cytotoxic trigger molecules for tumor cells.
Graziano RF; Fanger MW
J Immunol; 1987 Nov; 139(10):3536-41. PubMed ID: 2960735
[TBL] [Abstract][Full Text] [Related]
13. Section 1C: Assessment of the functional activity and IgG Fc receptor utilisation of 64 IgG Rh monoclonal antibodies. Coordinator's report.
Kumpel BM; Beliard R; Brossard Y; Edelman L; de Haas M; Jackson DJ; Kooyman P; Ligthart PC; Monchâtre E; Overbeeke MA; Puillandre P; de Romeuf C; Wilkes AM
Transfus Clin Biol; 2002 Jan; 9(1):45-53. PubMed ID: 11889899
[TBL] [Abstract][Full Text] [Related]
14. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
[TBL] [Abstract][Full Text] [Related]
15. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
16. VISTA is an activating receptor in human monocytes.
Rogers BM; Smith L; Dezso Z; Shi X; DiGiammarino E; Nguyen D; Sethuraman S; Zheng P; Choi D; Zhang D; Nguyen A; McGuire K; Liu W; Chung N; Chao DT; Ye S; Starbeck-Miller GR
J Exp Med; 2021 Aug; 218(8):. PubMed ID: 34106206
[TBL] [Abstract][Full Text] [Related]
17. Induction of T cell proliferation with anti-CD3 switch-variant monoclonal antibodies: effects of heavy chain isotype in monocyte-dependent systems.
Van Lier RA; Boot JH; De Groot ER; Aarden LA
Eur J Immunol; 1987 Nov; 17(11):1599-604. PubMed ID: 2960543
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the monocyte Fc receptors and antibody-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 antibodies.
Clement LT; Tilden AB; Dunlap NE
J Immunol; 1985 Jul; 135(1):165-71. PubMed ID: 3923099
[TBL] [Abstract][Full Text] [Related]
19. VISTA: A Target to Manage the Innate Cytokine Storm.
ElTanbouly MA; Zhao Y; Schaafsma E; Burns CM; Mabaera R; Cheng C; Noelle RJ
Front Immunol; 2020; 11():595950. PubMed ID: 33643285
[TBL] [Abstract][Full Text] [Related]
20. High-Affinity Anti-VISTA Antibody Protects against Sepsis by Inhibition of T Lymphocyte Apoptosis and Suppression of the Inflammatory Response.
Tao T; Bo L; Li T; Shi L; Zhang H; Ye B; Xu Y; Ma Q; Deng X; Zhang G
Mediators Inflamm; 2021; 2021():6650329. PubMed ID: 34366711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
